Guggenheim Capital’s AbbVie ABBV Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$53.4M Sell
245,701
-19,504
-7% -$4.33M 0.41% 42
2025
Q4
$60.6M Buy
265,205
+12,928
+5% +$2.95M 0.43% 37
2025
Q3
$58.4M Buy
252,277
+8,988
+4% +$1.83M 0.42% 41
2025
Q2
$45.2M Sell
243,289
-1,218
-0.5% -$226K 0.36% 57
2025
Q1
$51.2M Sell
244,507
-11,571
-5% -$2.25M 0.47% 39
2024
Q4
$45.5M Sell
256,078
-22,449
-8% -$4.13M 0.37% 51
2024
Q3
$55M Sell
278,527
-18,982
-6% -$3.54M 0.38% 43
2024
Q2
$51M Sell
297,509
-17,176
-5% -$2.85M 0.36% 48
2024
Q1
$57.3M Buy
314,685
+16,183
+5% +$2.79M 0.4% 41
2023
Q4
$46.3M Sell
298,502
-53,797
-15% -$7.84M 0.35% 49
2023
Q3
$52.5M Sell
352,299
-72,151
-17% -$10.6M 0.45% 33
2023
Q2
$57.2M Sell
424,450
-39,714
-9% -$5.82M 0.45% 28
2023
Q1
$74M Sell
464,164
-103,456
-18% -$15.8M 0.62% 15
2022
Q4
$91.7M Sell
567,620
-78,473
-12% -$12M 0.81% 8
2022
Q3
$86.7M Sell
646,093
-45,663
-7% -$6.55M 0.79% 7
2022
Q2
$106M Sell
691,756
-120,223
-15% -$18.4M 0.84% 7
2022
Q1
$132M Buy
811,979
+15,730
+2% +$2.28M 0.79% 11
2021
Q4
$108M Buy
796,249
+51,017
+7% +$6.03M 0.56% 21
2021
Q3
$80.4M Buy
745,232
+13,472
+2% +$1.54M 0.48% 23
2021
Q2
$82.4M Buy
731,760
+6,485
+0.9% +$730K 0.49% 22
2021
Q1
$78.5M Sell
725,275
-8,909
-1% -$953K 0.52% 17
2020
Q4
$78.7M Sell
734,184
-1,058
-0.1% -$102K 0.49% 22
2020
Q3
$64.4M Sell
735,242
-61,122
-8% -$5.75M 0.47% 23
2020
Q2
$78.2M Buy
796,364
+101,789
+15% +$8.96M 0.6% 14
2020
Q1
$52.9M Sell
694,575
-40,234
-5% -$3.43M 0.53% 17
2019
Q4
$65.1M Buy
734,809
+91,269
+14% +$7.58M 0.49% 20
2019
Q3
$48.7M Sell
643,540
-12,979
-2% -$890K 0.39% 35
2019
Q2
$47.7M Sell
656,519
-24,087
-4% -$1.89M 0.39% 34
2019
Q1
$54.9M Buy
680,606
+86,734
+15% +$7.1M 0.45% 24
2018
Q4
$54.7M Sell
593,872
-124,066
-17% -$10.9M 0.46% 20
2018
Q3
$67.9M Sell
717,938
-60,188
-8% -$5.71M 0.44% 17
2018
Q2
$72.1M Sell
778,126
-711,508
-48% -$69.5M 0.48% 14
2018
Q1
$141M Sell
1,489,634
-247,522
-14% -$27.2M 0.34% 13
2017
Q4
$168M Buy
1,737,156
+95,342
+6% +$8.99M 0.4% 8
2017
Q3
$146M Sell
1,641,814
-161,032
-9% -$12.3M 0.34% 14
2017
Q2
$131M Buy
1,802,846
+26,668
+2% +$1.79M 0.35% 14
2017
Q1
$116M Sell
1,776,178
-227,273
-11% -$14.3M 0.31% 15
2016
Q4
$125M Buy
2,003,451
+85,840
+4% +$5.24M 0.36% 11
2016
Q3
$121M Buy
1,917,611
+15,410
+0.8% +$998K 0.38% 12
2016
Q2
$118M Buy
1,902,201
+118,087
+7% +$7.2M 0.37% 12
2016
Q1
$102M Buy
1,784,114
+236,911
+15% +$13.2M 0.32% 23
2015
Q4
$91.7M Sell
1,547,203
-26,301
-2% -$1.51M 0.27% 34
2015
Q3
$85.6M Sell
1,573,504
-330,563
-17% -$21.5M 0.26% 32
2015
Q2
$128M Buy
1,904,067
+188,347
+11% +$12.3M 0.32% 15
2015
Q1
$100M Buy
1,715,720
+266,677
+18% +$16.1M 0.24% 39
2014
Q4
$94.8M Sell
1,449,043
-150,646
-9% -$9.5M 0.24% 46
2014
Q3
$92.4M Buy
1,599,689
+229,750
+17% +$12.8M 0.22% 44
2014
Q2
$77.3M Sell
1,369,939
-843,017
-38% -$44.2M 0.2% 71
2014
Q1
$114M Buy
2,212,956
+718,829
+48% +$36.3M 0.32% 12
2013
Q4
$78.9M Buy
1,494,127
+107,838
+8% +$5.3M 0.24% 42
2013
Q3
$62M Buy
1,386,289
+371,631
+37% +$16.5M 0.22% 52
2013
Q2
$41.9M Buy
+1,014,658
New +$44.4M 0.18% 84

Other funds holding ABBV

Guggenheim Capital's ABBV Position: Q1 2026 in Review

Guggenheim Capital reduced its AbbVie (ABBV) stake by 7.4% in Q1 2026, selling an estimated $4.33M and leaving 245,701 shares worth $53.4M. The position accounts for 0.41% of the portfolio, ranked #42.

Guggenheim Capital first reported a position in ABBV in Q2 2013 and has held it in 52 quarters since. The position peaked at $168M in Q4 2017. 4,075 funds tracked by Wall St. Rank hold ABBV as of Q1 2026.

  • Guggenheim Capital held 245,701 shares of AbbVie worth $53.4M as of Q1 2026.
  • Guggenheim Capital sold 19,504 AbbVie shares in Q1 2026, an estimated $4.33M.
  • AbbVie made up 0.41% of Guggenheim Capital's portfolio in Q1 2026, its #42 holding.
  • Guggenheim Capital first reported a position in AbbVie in Q2 2013 and has held it in 52 quarters since.
  • Guggenheim Capital's AbbVie position peaked at $168M in Q4 2017.
  • 4,075 funds tracked by Wall St. Rank held AbbVie as of Q1 2026.

Based on Guggenheim Capital's 13F filing for Q1 2026, filed 15 May 2026.